On Target Laboratories

On Target Laboratories company information, Employees & Contact Information

On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery so cancerous tissue can be removed more completely. To date, there has been no reliable way for surgeons to assess the location and full extent of cancerous tissue while operating. Our molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, aims to reduce the uncertainty associated with finding and removing cancerous tissue during surgical procedures, helping surgeons to provide a more precise and complete surgical resection. Visit our website to learn more about On Target Laboratories and our targeted intraoperative molecular imaging agents.

Company Details

Employees
58
Founded
-
Address
1281 Win Hentschel Blvd, West Lafayette,indiana 47906,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
West Lafayette, Indiana
Looking for a particular On Target Laboratories employee's phone or email?

On Target Laboratories Questions

News

On Target Laboratories Appoints Bill Peters as CEO - PR Newswire

On Target Laboratories Appoints Bill Peters as CEO PR Newswire

On Target Laboratories’ cancer illuminating technology receives Special Protocol Assessment from FDA - Purdue University

On Target Laboratories’ cancer illuminating technology receives Special Protocol Assessment from FDA Purdue University

On Target Laboratories Announces Expanded Indication of CYTALUX® (pafolacianine) - MultiVu

On Target Laboratories Announces Expanded Indication of CYTALUX® (pafolacianine) MultiVu

On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection - PR Newswire

On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection PR Newswire

On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection - PR Newswire

On Target Laboratories Secures $30 Million for Commercialization of CYTALUX® (pafolacianine) injection PR Newswire

On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery - PR Newswire

On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery PR Newswire

On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine Sodium Injection for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer - PR Newswire

On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine Sodium Injection for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer PR Newswire

On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian and Lung Cancer Indications - PR Newswire

On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian and Lung Cancer Indications PR Newswire

On Target Laboratories Completes ELUCIDATE Phase 3 Clinical Trial Investigating the Use of CYTALUX™ (pafolacianine) injection in Cancer in the Lung - PR Newswire

On Target Laboratories Completes ELUCIDATE Phase 3 Clinical Trial Investigating the Use of CYTALUX™ (pafolacianine) injection in Cancer in the Lung PR Newswire

Top On Target Laboratories Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant